182 filings
Page 2 of 10
8-K
g7tknmaxrt2vb8xngm2
15 May 23
Zevra Therapeutics Reports Corporate Updates and First Quarter 2023 Financial Results
4:14pm
8-K
1rjj3
8 May 23
Departure of Directors or Certain Officers
7:44am
8-K
4s1l mw16
26 Apr 23
Submission of Matters to a Vote of Security Holders
4:30pm
8-K
azjsi7zt2vts2nd
30 Mar 23
Departure of Directors or Certain Officers
9:12am
8-K
s15neu ke7pdcl7xxg
13 Mar 23
Regulation FD Disclosure
6:25am
8-K
gmbpnkp
7 Mar 23
Zevra Therapeutics Reports Fourth Quarter and Fiscal Year 2022 Financial Results and Corporate Updates
8:20am
8-K
xrbyfk
27 Feb 23
Regulation FD Disclosure
4:47pm
8-K
p78lf
23 Feb 23
Amendments to Articles of Incorporation or Bylaws
9:29pm
8-K
ew4rob32l d87lhw3
24 Jan 23
KemPharm Issues Letter to Shareholders
8:24pm
8-K
kam52yql
20 Jan 23
Other Events
5:05pm
8-K
4ez7 7aqm2h
9 Jan 23
Departure of Directors or Certain Officers
7:27am
8-K
7kqv721lbo
29 Nov 22
Departure of Directors or Certain Officers
7:53am
8-K
9guyu quzamieqrpf9gw
18 Nov 22
Other Events
8:17am
8-K
04n3q7q
9 Nov 22
KemPharm Reports Third Quarter 2022 Results
4:24pm
8-K
ndp8eruieqwkxpgxq
11 Aug 22
KemPharm Reports Second Quarter 2022 Financial Results and Corporate Updates
4:25pm
8-K
7argpypr
1 Jul 22
Submission of Matters to a Vote of Security Holders
8:32am
8-K
dml1g6sp69yy7y9p
17 Jun 22
Changes in Registrant's Certifying Accountant
9:14am
8-K
jqzqh5ogr5
31 May 22
Entry into a Material Definitive Agreement
9:13pm
8-K
1b33gs0l bmq1xwq3k
16 May 22
KemPharm Announces Strategic Acquisition of Arimoclomol from Orphazyme, Expanding its Rare CNS Diseases Pipeline
8:40am
8-K
dqqqafoaoql
12 May 22
KemPharm Reports First Quarter 2022 Financial Results and Corporate Updates
4:48pm